Stretch Armstrong was made to be pulled out of shape. Children could grab the toy by its arms and legs and stretch it far beyond its normal size. If you didn’t pull too hard, it would return to its resting form. Some recent claims about prescription drug savings invite the same kind of pulling — across speeches, press releases, and televised announcements. The question is what happens when the pulling stops.
The Trump administration has not merely claimed progress on drug prices. It has described its record in sweeping terms, sometimes with numbers that are mathematically impossible. In November 2025, Trump said his administration was delivering “tremendous cuts” of “200%, 300%, 500%, 700%, and even more than that.” Later in the same appearance, he said drug prices would go down “600, 700, 800%.” In April 2026, the Associated Press (AP) reported that when pressed, Trump conceded he also cites cuts of “50%, 60%” and “70, 80 and 90%,” calling these and his earlier 500% and 600% figures “two ways of calculating” the same thing. They are not. A price cannot fall by more than 100% unless the seller pays the buyer to take the product.
Public evidence supports a narrower story. The administration’s drug-pricing efforts fall mainly into three categories: Medicare negotiated prices, TrumpRx cash-pay discounts, and most-favored-nation-style manufacturer agreements. The drug-savings story is partly inherited, partly overstated, and partly unproven.
Medicare negotiated prices: real savings, weak attribution
The strongest savings claim involves Medicare drug price negotiation. The first 10 negotiated Medicare Part D prices took effect on January 1, 2026. CMS estimated that, if those negotiated prices had applied to 2023 Medicare spending, they would have saved about $6 billion in net covered prescription drug costs, or 22% across the selected drugs. CMS also estimated that Medicare beneficiaries would save $1.5 billion in out-of-pocket costs when the prices took effect in 2026.
Medicare negotiation is the most concrete part of the administration’s savings story. The drugs are known. The negotiated prices are public. The program is operating. The evidence is stronger than it is for TrumpRx or the manufacturer agreements.
The political attribution is much weaker. Medicare negotiation was created by the Inflation Reduction Act of 2022, and the first 10 negotiated prices were announced in August 2024, before Trump returned to office. The administration has nonetheless framed the program as its own. When CMS announced the second round of negotiated prices in November 2025, HHS Secretary Robert F. Kennedy Jr. said “President Trump directed us to stop at nothing to lower health care costs for the American people.” The Trump administration can fairly say these prices took effect while it was in office. The savings are not the product of its drug-pricing agenda.
The $6 billion figure is a projection, not an audited result. CMS has not reported an audited total of actual 2026 savings. It estimated what Medicare would have saved if the 2026 negotiated prices had applied to 2023 spending. That counterfactual estimate is useful, but it is not a final accounting of savings achieved in 2026.
Medicare negotiation stretches least on evidence and most on ownership. The savings are real. The political credit is not.
TrumpRx: big promotional claims, unverified savings
TrumpRx is the administration’s most visible drug-pricing initiative. The White House described its launch as “delivering massive, immediate savings to millions of Americans” and called TrumpRx.gov a “transformative new government platform” giving Americans access to “dramatically lower prices” on dozens of common, high-cost brand-name drugs. The White House pointed to specific price reductions. It said Ozempic and injectable Wegovy would drop from $1,028 and $1,349, respectively, to an average of $350 and as low as $199, depending on dosage. It said Zepbound would fall from $1,088 to an average of $346 and as low as $299. It also said fertility patients could save more than $2,000 per cycle on common medications.
Some patients likely will save money through these offers — especially the uninsured, those who have not met a deductible, and those seeking a drug their insurance does not cover. But the administration has not shown that TrumpRx has produced large overall savings.
KFF describes TrumpRx as a search tool for discounted brand-name drugs when patients pay without insurance. Patients do not buy drugs from TrumpRx itself. For many products, TrumpRx sends patients to manufacturer coupons or manufacturer-linked purchase channels.
The administration has not disclosed how many prescriptions were filled through TrumpRx-linked discounts, what patients would otherwise have paid, whether those patients had insurance, whether a cheaper generic was available, or whether the same discount was already available somewhere else.
Lower-cost generics undercut some of the advertised savings. KFF found that about half of the drugs on TrumpRx had generic equivalents available in the United States. For at least 17 of those 22 drugs, the generic was less expensive through GoodRx or Cost Plus Drugs than the TrumpRx coupon price for the brand-name version. The same KFF report also noted that TrumpRx does not tell consumers that a generic alternative may cost less.
On May 18, 2026, the administration announced an expansion of TrumpRx to include more than 600 generic medications. AP reported that the expansion was a response to criticism that many TrumpRx brand-name drugs had cheaper generic versions available elsewhere. The expansion may broaden the site’s usefulness for cash-paying patients, but it does not by itself establish realized savings.
MFN manufacturer agreements: expansive claims, hidden terms
The manufacturer agreements are the least transparent part of the administration’s drug-pricing record. “Most favored nation,” or MFN, refers here to an effort to align U.S. drug prices with lower prices paid in comparable countries. The White House says the Regeneron agreement marked Trump’s 17th MFN deal and that the deals now cover the 17 leading pharmaceutical manufacturers, representing 86% of the branded drug market. It also says each manufacturer agreed to “fundamentally rebalance international drug pricing” by providing MFN pricing to American patients.
The Regeneron announcement illustrates the gap between a posted price and verifiable savings. Reuters reported that Regeneron agreed to reduce Medicaid prices for current and future medications and sell the cholesterol drug Praluent through TrumpRx for $225, down from $537. A lower posted TrumpRx price for Praluent may help some cash-paying patients. It does not show how much Medicaid or patients have saved overall.
Medicaid savings cannot be verified from sticker-price comparisons. The relevant number is the net price after rebates, state-specific arrangements, utilization, and any “best-price” effects. A serious savings estimate would need the prior Medicaid net price, the new net price, the number of prescriptions affected, and the treatment of rebates and other concessions. Most of these figures are confidential by federal law, which means even careful outside analysts cannot verify the savings independently.
The administration has not released the data needed to verify Medicaid savings. KFF reports that the details of these MFN agreements remain confidential, and that the full scope of the deals—including which drugs are subject to them, what specific pricing has been agreed to, and how MFN prices are determined—is largely unknown. The AP similarly reported that the details of the Regeneron agreement and related deals have not been made public, with the administration citing proprietary and trade-secret concerns.
Some Medicaid programs or cash-paying patients may pay less under the manufacturer agreements. But the administration has not released enough information to verify the size of those savings. Until it does, the MFN claims remain claims, not verified facts.
Inherited, overstated, and unproven
Medicare negotiation has the strongest support, but the savings come from a program created before Trump returned to office. TrumpRx may help some cash-paying patients, but the administration has not released the data needed to show overall savings. The manufacturer agreements may reduce some prices, but the key terms remain hidden.
The impossible percentage claims are the most hyperbolic part of the administration’s drug-savings rhetoric. Those numbers are not merely exaggerated. As price reductions, they are impossible.
Stretch Armstrong was sold on a promise: Pull him as far as you like, and he will return to shape. The promise had a limit. Stretch him too far and he tears. A stretched claim behaves the same way. Pulled past what the evidence can support, it may seem to snap back when corrected. But corrections do not reach everyone, and some corrections cannot be made at all, because you cannot correct what is hidden. What is left is the stretched claim.
No Comments